Search for: "Watson Pharmaceuticals, Inc"
Results 1 - 20
of 225
Sort by Relevance
|
Sort by Date
19 Feb 2024, 12:55 pm
Watson, 188 F. [read post]
17 Jan 2023, 6:30 am
Watson Labs., Inc. [read post]
17 Jan 2023, 6:30 am
Watson Labs., Inc. [read post]
17 Jan 2023, 6:30 am
Watson Labs., Inc. [read post]
29 Aug 2022, 9:05 pm
Since President Biden issued his July 2021 Executive Order on Competition, the antitrust agencies have made broad policy statements promising more aggressive enforcement and have initiated a number of high-profile enforcement actions. [read post]
28 Dec 2021, 9:42 am
Inc., Case No. 18stcv04283 (Cal. [read post]
19 Apr 2021, 9:37 am
Aon, which clinched the deal a year ago to create the world’s largest insurance broker ahead of Marsh & McLennan Companies Inc, submitted concessions to the European Union’s competition watchdog last Friday, an EU filing showed. [read post]
16 Jun 2020, 9:59 pm
Watson Laboratories Inc. and Galderma Laboratories, L.P. v. [read post]
17 Nov 2018, 12:10 pm
“Then time will tell just who fellAnd who’s been left behind” Dylan, “Most Likely You Go Your Way” (1966) When the Daubert case headed to the Supreme Court, it had 22 amicus briefs in tow. [read post]
14 Apr 2018, 11:46 am
Watson Labs., Inc. [read post]
7 Dec 2017, 9:34 pm
Seeking approval to market generic versions of Eli Lilly's Axiron® testosterone applicator, Defendants Perrigo Company and Perrigo Israel Pharmaceuticals Ltd., Actavis Laboratories UT, Inc., FKA Watson Laboratories Inc., Lupin Pharmaceuticals, Inc. and Lupin Ltd., and Amneal Pharmaceuticals LLC filed... [read post]
Court Of Appeals For Federal Circuit Denies Eli Lilly’s Appeal, Opens Door for Testosterone Generics
5 Dec 2017, 12:29 pm
., and Acrux DDS Pty Ltd. had filed a patent infringement lawsuit in the Southern District of Indiana alleging that Defendants, Perrigo Company, Perrigo Israel Pharmaceuticals Ltd., Actavis Laboratories UT, Inc., FKA Watson Laboratories Inc., Lupin Pharmaceuticals, Inc., and Lupin LTD infringed patent no. 8,435,944, Method and Composition for Transdermal Drug Delivery (the ‘944 patent) and 8,807,861, Spreading Implement, (the ‘861… [read post]
8 Nov 2017, 7:26 am
Paul Insurance companies owe no duty to defend or indemnify Watson Pharmaceutical in governmental suits against the pharmaceutical company over the deceptive marketing of opioids. [read post]
17 Jul 2017, 4:20 pm
Watson Pharmaceuticals, Inc. [read post]
6 Apr 2017, 1:35 pm
Mylan, Inc., No. 15-1113(Fed. [read post]
5 Apr 2017, 9:08 am
With respectto Watson, the PTAB found that it “does not controlhere because [Appellee] Noven [Pharmaceuticals Inc. [read post]
15 Feb 2017, 2:49 pm
Watson Pharmaceuticals, Inc., February 10, 2017, Hughes, T.). [read post]
14 Feb 2017, 9:13 pm
The lawsuit involved Watson's ANDA filing seeking approval for a generic version of Shire's controlled-release oral pharmaceutical composition for the treatment of inflammatory bowel disease, Crohn's disease, and ulcerative colitis, sold by Shire under the brand name LIALDA®. [read post]
8 Feb 2017, 3:09 am
Teva Pharmaceuticals USA, Inc., et al. [read post]
23 Jan 2017, 1:25 am
The CJEU’s recent decision in the Tele2/Watson case may call the viability of the new Investigatory Powers Act into question. [read post]
